SCR-1693 inhibits tau phosphorylation and improves insulin resistance associated cognitive deficits

[1]  Jian-Zhi Wang,et al.  Methanolic extract of Tamarix Gallica attenuates hyperhomocysteinemia induced AD-like pathology and cognitive impairments in rats , 2018, Aging.

[2]  N. Kimura.  Diabetes Mellitus Induces Alzheimer’s Disease Pathology: Histopathological Evidence from Animal Models , 2016, International journal of molecular sciences.

[3]  L. Luo,et al.  A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Aβ25–35-impaired mouse cognitive function , 2016, Psychopharmacology.

[4]  Saadia Zahid,et al.  Linking insulin with Alzheimer’s disease: emergence as type III diabetes , 2015, Neurological Sciences.

[5]  Paul A Insel,et al.  Experimental design and analysis and their reporting: new guidance for publication in BJP , 2015, British journal of pharmacology.

[6]  G. Bedse,et al.  Aberrant insulin signaling in Alzheimer's disease: current knowledge , 2015, Front. Neurosci..

[7]  Q. Tian,et al.  A novel tacrine-dihydropyridine hybrid (-)SCR1693 induces tau dephosphorylation and inhibits Aβ generation in cells. , 2015, European journal of pharmacology.

[8]  K. Chopra,et al.  Neuroprotective potential of sesamol and its loaded solid lipid nanoparticles in ICV-STZ-induced cognitive deficits: behavioral and biochemical evidence. , 2015, European journal of pharmacology.

[9]  C. Nath,et al.  Protection of streptozotocin induced insulin receptor dysfunction, neuroinflammation and amyloidogenesis in astrocytes by insulin , 2014, Neuropharmacology.

[10]  Jian-Zhi Wang,et al.  Magnesium Protects Cognitive Functions and Synaptic Plasticity in Streptozotocin-Induced Sporadic Alzheimer’s Model , 2014, PloS one.

[11]  Jun Yin.  TAU PROTEIN INDUCES INSULIN RESISTANCE THROUGH JNK PATHWAY , 2014, Alzheimer's & Dementia.

[12]  S. Arnold,et al.  Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease , 2014, Diabetes.

[13]  J. Sontag,et al.  Protein phosphatase 2A dysfunction in Alzheimer’s disease , 2014, Front. Mol. Neurosci..

[14]  S. Rai,et al.  Glial activation and post-synaptic neurotoxicity: The key events in Streptozotocin (ICV) induced memory impairment in rats , 2014, Pharmacology Biochemistry and Behavior.

[15]  A. Bretteville,et al.  Insulin dysfunction and Tau pathology , 2013, Front. Cell. Neurosci..

[16]  Jing Wu,et al.  Tau pathology in diabetes mellitus. , 2013, Die Pharmazie.

[17]  D. Postma,et al.  Glycogen synthase kinase‐3 (GSK‐3) regulates TGF‐β1‐induced differentiation of pulmonary fibroblasts , 2013, British journal of pharmacology.

[18]  Fei Liu,et al.  A Non-transgenic Mouse Model (icv-STZ Mouse) of Alzheimer’s Disease: Similarities to and Differences from the Transgenic Model (3xTg-AD Mouse) , 2013, Molecular Neurobiology.

[19]  Cornelia M. Wilson,et al.  Tau protein kinases: Involvement in Alzheimer's disease , 2013, Ageing Research Reviews.

[20]  Cornelia M. Wilson,et al.  Tau protein phosphatases in Alzheimer's disease: The leading role of PP2A , 2013, Ageing Research Reviews.

[21]  F. LaFerla,et al.  Brain Gene Expression of a Sporadic (icv-STZ Mouse) and a Familial Mouse Model (3xTg-AD Mouse) of Alzheimer’s Disease , 2012, PloS one.

[22]  J. Sowers,et al.  Phosphoprotein Phosphatase PP2A Regulation of Insulin Receptor Substrate 1 and Insulin Metabolic Signaling , 2012, Cardiorenal Medicine.

[23]  M. Nishizawa,et al.  Hyperphosphorylation of Tau Induced by Naturally Secreted Amyloid-β at Nanomolar Concentrations Is Modulated by Insulin-dependent Akt-GSK3β Signaling Pathway* , 2012, The Journal of Biological Chemistry.

[24]  D. Ruano,et al.  Age-dependent Accumulation of Soluble Amyloid β (Aβ) Oligomers Reverses the Neuroprotective Effect of Soluble Amyloid Precursor Protein-α (sAPPα) by Modulating Phosphatidylinositol 3-Kinase (PI3K)/Akt-GSK-3β Pathway in Alzheimer Mouse Model* , 2011, The Journal of Biological Chemistry.

[25]  R. Agrawal,et al.  Insulin receptor signaling in rat hippocampus: A study in STZ (ICV) induced memory deficit model , 2011, European Neuropsychopharmacology.

[26]  I. Cuthill,et al.  Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.

[27]  R. Agrawal,et al.  Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. , 2010, Pharmacological research.

[28]  A. Nairn,et al.  PP1-mediated dephosphorylation of phosphoproteins at mitotic exit is controlled by inhibitor-1 and PP1 phosphorylation , 2009, Nature Cell Biology.

[29]  R. Agrawal,et al.  A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia , 2009, Neuropharmacology.

[30]  J. Wands,et al.  Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed , 2008, Journal of diabetes science and technology.

[31]  J. Luchsinger,et al.  Insulin Dysfunction Induces In Vivo Tau Hyperphosphorylation through Distinct Mechanisms , 2007, The Journal of Neuroscience.

[32]  H. Tanila,et al.  Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology , 2007, Journal of cellular and molecular medicine.

[33]  A. Nairn,et al.  Regulation of Protein Phosphatase Inhibitor-1 by Cyclin-dependent Kinase 5* , 2007, Journal of Biological Chemistry.

[34]  M. Zvelebil,et al.  Exploring the specificity of the PI3K family inhibitor LY294002. , 2007, The Biochemical journal.

[35]  P. Riederer,et al.  Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein , 2007, Journal of neurochemistry.

[36]  A. Zmijewska,et al.  Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain In Vivo After Streptozotocin-Induced Insulin Deficiency , 2006, Diabetes.

[37]  A. Lochner,et al.  The many faces of H89: a review. , 2006, Cardiovascular drug reviews.

[38]  P. Riederer,et al.  Alzheimer‐like changes in protein kinase B and glycogen synthase kinase‐3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway , 2006, Journal of neurochemistry.

[39]  Fei Liu,et al.  Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation , 2005, The European journal of neuroscience.

[40]  G. Hart,et al.  O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[42]  J. Trojanowski,et al.  PP2A mRNA Expression Is Quantitatively Decreased in Alzheimer's Disease Hippocampus , 2001, Experimental Neurology.

[43]  G. Mills,et al.  Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Hoyer,et al.  Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. , 1998, Behavioral neuroscience.

[45]  P. Greengard,et al.  Cell cycle-dependent phosphorylation of mammalian protein phosphatase 1 by cdc2 kinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  I. Grundke‐Iqbal,et al.  Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5 , 1997, Molecular and Cellular Biochemistry.

[47]  I. Grundke‐Iqbal,et al.  Phosphatase Activity Toward Abnormally Phosphorylated τ: Decrease in Alzheimer Disease Brain , 1995, Journal of neurochemistry.

[48]  P. Greengard,et al.  Phosphorylation and inactivation of protein phosphatase 1 by cyclin-dependent kinases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  E. Van Obberghen,et al.  Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. , 1994, The Journal of biological chemistry.

[50]  P. Cohen,et al.  Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. , 1993, The Biochemical journal.

[51]  I. Grundke‐Iqbal,et al.  Phosphoprotein Phosphatase Activities in Alzheimer Disease Brain , 1993, Journal of neurochemistry.

[52]  J. Chen,et al.  Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. , 1992, Science.

[53]  Sterling C. Johnson,et al.  Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 Carriers. , 2015, Journal of Alzheimer's disease : JAD.

[54]  Q. Tian,et al.  Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats. , 2014, Journal of Alzheimer's disease : JAD.

[55]  Peng Liu,et al.  Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats , 2013, Psychopharmacology.

[56]  P. Riederer,et al.  Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. , 2009, Journal of Alzheimer's disease : JAD.

[57]  R. Honkanen,et al.  Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. , 2007, Methods in molecular biology.

[58]  S. Hoyer,et al.  Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. , 2007, Journal of neural transmission. Supplementum.

[59]  J. Wands,et al.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.

[60]  Y. Le Marchand-Brustel,et al.  Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. , 2005, Biochimie.

[61]  T Szkudelski,et al.  The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. , 2001, Physiological research.